Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-107306
Filing Date
2025-08-12
Accepted
2025-08-12 16:08:44
Documents
54
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q maze-20250630.htm   iXBRL 10-Q 2480794
2 EX-31.1 maze-ex31_1.htm EX-31.1 14643
3 EX-32.1 maze-ex32_1.htm EX-32.1 11625
  Complete submission text file 0000950170-25-107306.txt   7991569

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT maze-20250630.xsd EX-101.SCH 804261
56 EXTRACTED XBRL INSTANCE DOCUMENT maze-20250630_htm.xml XML 1404499
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Filer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42490 | Film No.: 251206723
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)